U.S. Food Stock News

NYSE:BABA
NYSE:BABAMultiline Retail

Alibaba (BABA) Joins Apple To Bring Qwen AI To Devices In China

Apple is partnering with Alibaba's Qwen AI to power on-device artificial intelligence services on Apple hardware in China. The collaboration follows regulatory approval and makes Qwen AI available across Apple devices in the Chinese market. The deal extends Alibaba Group Holding's (NYSE:BABA) generative AI reach into Apple's user base in the world's largest smartphone market. For Alibaba Group Holding, this partnership plugs its Qwen AI model directly into Apple's installed base in China,...
NYSE:AN
NYSE:ANSpecialty Retail

AutoNation (AN) Could Be 19% Below Fair Value After Porsche Hilton Head Opening

Expansion into a high growth luxury hub AutoNation (AN) is drawing fresh investor attention after opening Porsche Hilton Head, a 34,000-square-foot Generation 5 “Destination Porsche” retail and service center in South Carolina’s fast-growing Lowcountry region. See our latest analysis for AutoNation. The opening of Porsche Hilton Head comes as AutoNation’s share price trades at US$196.28, with a 1-day share price return of 1.47% and a 5-year total shareholder return of 71.92%. This suggests...
NYSE:OMC
NYSE:OMCMedia

Omnicom Group (OMC) Adds Leaders And Highlights AI Commerce, Is It Still Below Fair Value?

Omnicom Group (OMC) is back in focus after its Interbrand unit added senior leaders in North America and Flywheel released new research on AI driven commerce, prompting investors to reassess the stock’s recent performance. See our latest analysis for Omnicom Group. At a share price of $80.75, Omnicom Group’s recent news on AI driven commerce and North American leadership changes comes after a 5.31% 30 day share price gain. Its 1 year total shareholder return of 18.67% contrasts with a 3 year...
NYSE:GSL
NYSE:GSLShipping

3 Shipping Stocks With 5% Yields Income Investors May Want To Watch

With inflation, interest rates and policy signals pulling markets in different directions, many investors are looking for income that feels more resilient than a headline yield on a bond or cash product. That is where Dividend Fortresses come in, focusing on stocks that currently offer 5%+ dividend yields and are built around balance sheet strength and consistent cash generation. In this article, you will see how this theme fits into today’s macro backdrop and get a closer look at three...
NYSE:FNB
NYSE:FNBBanks

Can F.N.B (FNB) Stay Cheap As Q2 Earnings Near?

F.N.B stock has almost doubled over the past five years, and the current checks suggest the market price is still below what its intrinsic value estimate and earnings multiples imply. F.N.B has returned 99.7% over five years, which puts extra focus on whether the current price still offers a margin relative to its underlying fundamentals. Expectations around upcoming earnings, including revenue and earnings per share, can support the current valuation, while any disappointment on...
NasdaqGS:SOFI
NasdaqGS:SOFIConsumer Finance

Is SoFi Technologies (SOFI) Cheap Ahead Of Earnings And Its New ETF Launch?

Investor focus on SoFi Technologies (SOFI) has sharpened ahead of second quarter earnings on July 29, as the company highlights financial services growth and introduces the SoFi Social 50 Income ETF for income focused investors. See our latest analysis for SoFi Technologies. SoFi Technologies’ recent 11.88% 1 month share price return and 4.51% 7 day share price return contrast with a year to date share price decline of 32.45%. At the same time, the 3 year total shareholder return of 93.83%...
NYSE:FCN
NYSE:FCNProfessional Services

FTI Consulting (FCN) After The Energy Hire That Put Fair Value Back In Focus

FTI Consulting (FCN) has drawn investor attention after appointing energy economist Emmanuel Fages as Senior Managing Director in its Energy & Utilities practice, adding deep sector expertise in energy transition and complex transactions. See our latest analysis for FTI Consulting. At a share price of $159.34, FTI Consulting has seen short term share price pressure, with a 1 day move that declined 1.41% and a 90 day share price return that declined 11.23%. The 5 year total shareholder return...
NYSE:AM
NYSE:AMOil and Gas

Antero Midstream (AM) Draws Valuation Focus, Is The Stock Still Undervalued?

Insider award puts fresh focus on Antero Midstream Antero Midstream (AM) drew investor attention after director Janine J. McArdle received a compensation-related award of 1,907 shares on July 10, 2026, lifting her direct holding to 82,424 shares. See our latest analysis for Antero Midstream. At a share price of $22.76, Antero Midstream has seen firm momentum, with a 30 day share price return of 5.03% and a year to date share price return of 26.87%, alongside a 5 year total shareholder return...
NYSE:PCG
NYSE:PCGElectric Utilities

PG&E (PCG) Faces $22 Million Penalty Over Mosquito Fire Violations

California regulators plan to penalize PG&E (NYSE:PCG) $22 million in connection with the 2022 Mosquito Fire. The proposed settlement from the California Public Utilities Commission cites violations in overhead electrical line design, construction, and maintenance. The action focuses on infrastructure issues that regulators say contributed to the Mosquito Fire. PG&E is a major California utility that provides electricity and gas to millions of customers, so infrastructure quality and...
NasdaqGS:CYTK
NasdaqGS:CYTKBiotechs

Cytokinetics (CYTK) Could Be 22% Undervalued On Its Growth Narrative

Cytokinetics (CYTK) is back in focus after president and CEO Robert I. Blum exercised options at US$10.60 and sold 7,500 shares around US$82, while retaining a large remaining stake. See our latest analysis for Cytokinetics. The recent insider activity comes against a backdrop of strong momentum for Cytokinetics, with the share price at US$81.93, a 30 day share price return of 16.79% and a 1 year total shareholder return of 115.55%. If you are weighing Cytokinetics against other healthcare...
NYSE:REXR
NYSE:REXRIndustrial REITs

Does Scotiabank’s Buyback-Focused Upgrade Change The Bull Case For Rexford Industrial Realty (REXR)?

Earlier this week, Scotiabank upgraded Rexford Industrial Realty to an Outperform rating, citing that much of the downside risk has already been reflected in the stock and pointing to recent management share repurchases as a supportive factor. This shift highlights how Rexford’s own capital allocation decisions, particularly buybacks, are influencing external confidence in the company’s underlying valuation. Next, we’ll examine how this upgraded view, grounded partly in Rexford’s share...
NYSE:LMT
NYSE:LMTAerospace & Defense

Is Lockheed Martin (LMT) Stock Still Reasonable After New Contract Wins?

Lockheed Martin stock has delivered a 55.1% total return over the past 5 years, yet current checks suggest the shares may still trade below an intrinsic value estimate, with both the Discounted Cash Flow (DCF) work and earnings multiples pointing to upside compared with the recent price near US$514.99. At the same time, the share price has eased in the short term, which raises the question of whether the pullback is creating a valuation opportunity or simply reflecting execution and contract...
NYSE:DIS
NYSE:DISEntertainment

Walt Disney (DIS) Faces Streaming Pressure, Is The Stock Undervalued?

Analyst debate after 'Moana' remake and streaming questions Walt Disney (DIS) is back in focus after its live action "Moana" remake underperformed earlier expectations at the box office, coinciding with analyst calls to reconsider the company’s commitment to direct to consumer streaming. This combination of a high profile release and fresh commentary from firms such as Wells Fargo has pushed investors to reassess how Disney’s extensive intellectual property and streaming platforms fit into...
NYSE:BX
NYSE:BXCapital Markets

Does Renewed Valuation Scrutiny Reveal a Strategic Crossroads for Blackstone (BX)'s Real Estate Exposure?

Recent commentary has revisited Blackstone’s mixed valuation, highlighting the balance between its large-scale, diversified platform and lingering headwinds tied to real estate exposure and uncertain asset realizations. An interesting takeaway is how fair-value models hint at potential upside even as traditional market multiples paint a more demanding picture for the firm. We’ll now examine how this renewed focus on valuation risks and real estate exposure could reshape Blackstone’s existing...
NasdaqGS:STLD
NasdaqGS:STLDMetals and Mining

3 Commodity Producer Stocks Retail Investors Are Watching For Inflation Protection

Stubborn inflation risk, the possibility of US CPI moving toward 5–6%, and 10 year Treasury yields that could head toward 8% are reshaping how investors think about both risk and opportunity across markets. Higher bond yields can pressure stock valuations, while a more hawkish Federal Reserve, now led by Kevin Warsh, may pull some of that pressure in the other direction. In this environment, commodity related producers stand out as one way to adjust exposure. This article breaks down three...
NasdaqGM:GHRS
NasdaqGM:GHRSPharmaceuticals

GH Research (GHRS) In Focus As FDA Psychedelic Shift Raises The Question Of Value

Regulatory shift puts GH Research (NasdaqGM:GHRS) in focus The US Food and Drug Administration’s finalized guidance on psychedelic drug development, along with a planned public hearing on supervised psychedelic use, has put GH Research (NasdaqGM:GHRS) firmly back on investors’ radar. This clearer regulatory direction may influence how investors think about regulatory risk, sector accessibility, and valuation frameworks for clinical-stage psychedelic developers, particularly those targeting...
NYSE:GE
NYSE:GEAerospace & Defense

General Electric (GE) Stock May Trade At A Premium On Cash Flow While Earnings Look Fair

After a very strong five year run that has seen General Electric return about 473%, the valuation backdrop has become more contentious, with the Discounted Cash Flow (DCF) intrinsic value estimate indicating the stock trades at a premium even as standard earnings multiples look roughly in line with peers. The roughly 473% total return over five years puts General Electric among the stronger performers in its sector, which naturally raises the bar for what counts as an appealing entry price...
NasdaqGS:INTU
NasdaqGS:INTUSoftware

Intuit (INTU) Faces Lawsuits And Investigations Over TurboTax Growth Claims

Multiple class action lawsuits allege Intuit and certain executives made false or misleading statements about TurboTax’s competitive position and growth. Regulators have opened legal investigations following workforce layoffs and weaker than expected tax season results. The company has acknowledged underperformance in parts of the tax business, contrasting with earlier public commentary highlighted in the lawsuits. Shareholders are assessing potential impacts on NasdaqGS:INTU related to...
NasdaqGM:TTD
NasdaqGM:TTDMedia

Trade Desk (TTD) Launches Japan Retail Data Tie Up With 28 Million 7 Eleven App Members

Trade Desk (NasdaqGM:TTD) has launched a major retail data integration with SEVEN-ELEVEN JAPAN. The partnership allows advertisers in Japan to use retail purchase data from 28 million 7-Eleven App members across digital channels. The integration focuses on scalable, always-on audience targeting that aims to respect consumer privacy requirements. Trade Desk operates a global advertising technology platform that connects advertisers to digital media across formats such as display, video, and...
NasdaqGS:ASML
NasdaqGS:ASMLSemiconductor

ASML (NasdaqGS:ASML) Lands High NA Chip Milestone As Intel Production Begins

ASML Holding (NasdaqGS:ASML) reports strong Q2 2026 results and raises its quarterly and full-year 2026 sales and margin guidance. Intel Foundry uses ASML's High NA EUV tools for production chips, marking the first high-volume output on this new lithography standard. Management cites robust AI-related demand and outlines plans for significant capacity expansion to support customers. ASML Holding sits at the center of advanced chip production, supplying lithography systems that are essential...
NasdaqGS:GRAL
NasdaqGS:GRALBiotechs

Is GRAIL (GRAL) Expensive After The NHS Galleri Trial Miss And Lawsuits?

GRAIL (GRAL) is in focus after multiple law firms filed securities fraud class action lawsuits, following disclosure that its NHS Galleri cancer trial did not meet its primary endpoint and was linked to sharp investor losses. See our latest analysis for GRAIL. After the initial 50% drop following the NHS Galleri trial disclosure, GRAIL's recent momentum has picked up, with a 30 day share price return of 22.17% and a 90 day share price return of 46.86%. The 1 year total shareholder return...
NYSE:RSG
NYSE:RSGCommercial Services

Republic Services (RSG) Heads Into Earnings As Its Fair Value Story Stays In Focus

Upcoming Q2 earnings put Republic Services in focus Republic Services (RSG) is back in the spotlight as it heads toward its fiscal second quarter 2026 earnings release on Thursday, August 6, after the market close. This update is one that many investors watch closely. Analysts expect profit of $1.81 per share for the quarter, compared with the same period a year ago. Republic Services has met or exceeded Wall Street EPS estimates in each of the last four quarters. See our latest analysis for...
NYSE:CRM
NYSE:CRMSoftware

Salesforce (CRM) Launches Advisor AI Partnerships And Real Time Data Quality Tools

Salesforce (NYSE:CRM) is seeing fresh product momentum as Quik! and High Meadow Solutions launch Quik! for Salesforce to bring AI-driven, form-based advisor workflows directly into the CRM. DataGroomr has rolled out real-time cross-object duplicate prevention on Salesforce, targeting cleaner data across Leads, Contacts, and other core records. These updates arrive as Salesforce trades around $167.56 and continues to position itself as a core platform for AI, compliance workflows, and data...
NasdaqGS:REGN
NasdaqGS:REGNBiotechs

Regeneron Pharmaceuticals (REGN) Stumbled In A Trial Setback, Is The Stock Still Cheap?

Clinical trial setback shifts attention to Regeneron Pharmaceuticals pipeline Regeneron Pharmaceuticals (REGN) is back in focus after disappointing clinical trial results for one of its pipeline drugs, which weighed on recent performance and pushed investor attention toward unmet development milestones. At the same time, therapies Dupixent and Eylea remain key anchors for the business. Regeneron Pharmaceuticals has been repurchasing shares and avoiding value destructive acquisitions, a...